

厚生労働行政推進調査事業費補助金（肝炎等克服政策研究事業）
総括研究報告書

肝がん研究の推進及び肝がん患者等への支援のための最適な仕組みの構築を目指した研究

研究代表者 小池和彦 東京大学医学部附属病院 教授

研究要旨 平成 30 年度より開始される新たな肝がん・重度肝硬変治療研究促進事業開始にあたり、協議の上、対象患者及び対象医療を判定する方法と認定基準、指定医療機関の認定基準を定め、マニュアル等を作成した。肝がんの再発防止等を念頭においた研究を促進するため収集すべき臨床データ項目を肝がん研究会追跡調査項目に準拠して決定し、プラットフォームとして National Clinical Database(NCD)を採用することを決定した。本結果は平成 30 年度からの治療研究促進事業実施に資するものとする。

（研究分担者）

泉 並木 武蔵野赤十字病院 院長
考藤達哉 国立国際医療研究センター 肝炎・
免疫研究センター センター長
工藤正俊 近畿大学医学部 主任教授
久保正二 大阪市立大学大学院医学研究科
准教授
宮田裕章 慶應義塾大学医学部 教授
建石良介 東京大学医学部附属病院 特任講師

1) 認定基準

対象医療の範囲について、自施設の患者リストを参照しながら、ICD-10、医科診療報酬点数表、DPC コード、標準病名マスターデータベースを検索、検討した。

2) 指定医療機関の要件

指定医療機関の要件について、協議した。

3) 臨床データ収集のプラットフォームとして、National Clinical Database(NCD)を念頭に、日本肝がん研究会全国原発性肝がん追跡調査の調査項目を元に収集すべきデータについて協議を行った。

（倫理面への配慮）

自施設の肝がん患者データの閲覧にあたっては、「人を対象とする医学系研究に関する倫理指針」に沿った東京大学医学部附属病院消化器内科「消化器疾患の治療成績・長期予後に関する研究」(承認番号 2058-(3))の範囲内で行った。

C. 研究結果

1) 検討結果、ICD-10 コードでは一つの病名のカバーする範囲が広すぎ、DPC コードでは、原発と続発の区別を付けることができないことが判明した。電子カルテ用 ICD10 対応標準

A. 研究目的

平成 30 年度より開始される新たな肝がん・重度肝硬変治療研究促進事業開始にあたって、対象患者や対象医療を判定する方法と認定基準を定め、マニュアル等を作成すること、同事業における指定医療機関および臨床データ収集医療機関の要件を決定すること、および肝がんの再発防止等を念頭においた研究を促進するために収集すべき臨床データの詳細、およびどのようなプラットフォームを用いてデータ収集を行うかを決定することを目的とした。

B. 研究方法

病名マスターは、「1つの病気（疾患）に1病名表現、1病名コード」を実現するために作成された病名一覧表であり、診療現場では電子カルテ及び診療報酬請求の病名指定に用いられており、実臨床の観点から最適であると判断した。これらを用いて対象患者、医療行為の範囲を決定した。

2) 協議の結果、指定医療期間として「ウイルス肝炎およびそこから生じた肝がん・肝硬変の診療行為を行う事ができる医療機関」と定義し、肝疾患専門医療機関、肝疾患診療連携拠点病院、がん診療連携拠点病院、地域がん診療病院、特定領域がん診療連携拠点病院等を含むものと決定した。

3) NCD事務局と協議の上、NCDデータベース上に本研究のためのプラットフォームを問題なく構築できる事を確認した。収集すべきデータ項目について肝癌研究会追跡調査項目に準拠しつつ、複数回入院のデータを収集できるよう拡張を行った。肝硬変部分に関しては、新たに収集項目の原案を作成した。

D. 考察

具体的かつ妥当な認定要件を設定することができた。データベース構築にあたって、必要な準備は終了したので、平成30年度からはデータベース構築を遅滞なく行う事ができるものと思われる。

E. 結論

当初掲げた3つの目的について必要かつ十分な成果が得られたものと考えられる。本結果は平成30年度からの治療研究促進事業実施に資するものとする。

F. 健康危険情報

特になし。

G. 研究発表

1) 論文発表（発表誌名巻号・頁・発行年等も記入）

1. Koike K, Suyama K, Ito H, Itoh H, Sugiura W.; Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients. *Hepatol Res.* 2018;48(1):59-68.
2. Joshita S, Yoshizawa K, Umemura T, Ohira H, Takahashi A, Harada K, Hiep NC, Tsuneyama K, Kage M, Nakano M, Kang JH, Koike K, Zeniya M, Yasunaka T, Takaki A, Torimura T, Abe M, Yokosuka O, Tanaka A, Takikawa H.; Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey. *J Gastroenterol.* 2018;[Epub].
3. Iwasa M, Karino Y, Kawaguchi T, Nakaniishi H, Miyaaki H, Shiraki M, Nakajima T, Sawada Y, Yoshiji H, Okita K, Koike K.; Relationship of muscle cramps to quality of life and sleep disturbance in patients with chronic liver diseases: a nationwide study. *Liver Int.* 2018;[Epub].
4. Hiramine Y, Uojima H, Nakanishi H, Hiramatsu A, Iwamoto T, Kimura M, Kawaratani H, Terai S, Yoshiji H, Uto H, Sakaida I, Izumi N, Okita K, Koike K.; Response criteria of tolcapton for the treatment of hepatic edema. *J Gastroenterol.* 2018;53(2):258-268.
5. Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, Tanaka Y, Tateishi R, Hikiba Y, Misumi K, Tanaka M, Hayashi A, Shibahara J, Fukayama M, Arita J, Hasegawa K, Hirschfield H, Hoshida Y, Hirata Y, Otsuka M, Tateishi K, Koike K.; CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcin-

- ogenesis via acylcarnitine accumulation in obesity. *Gut* 2018;[Epub].
6. Takata A, Otsuka M, Kishikawa T, Yamagami M, Ishibashi R, Sekiba K, Suzuki T, Ohno M, Yamashita Y, Abe T, Masuzaki R, Ikenoue T, Koike K.; RASAL1 is a potent regulator of hepatic stellate cell activity and liver fibrosis. *Oncotarget*. 2017;8(39):64840-64852.
 7. Sekiba K, Yamagami M, Otsuka M, Suzuki T, Kishikawa T, Ishibashi R, Ohno M, Sato M, Koike K.; Transcriptional activation of the MICA gene with an engineered CRISPR-Cas9 system. *Biochem Biophys Res Commun*. 2017;486(2):521-525.
 8. Sato M, Tateishi R, Yasunaga H, Matsui H, Horiguchi H, Fushimi K, Koike K.; Mortality and hemorrhagic complications associated with radiofrequency ablation for treatment of hepatocellular carcinoma in patients on hemodialysis for end-stage renal disease: A nationwide survey. *J Gastroenterol Hepatol*. 2017;32(11):1873-1878.
 9. Nakagawa R, Muroyama R, Saeki C, Goto K, Kaise Y, Koike K., Nakano M, Matsubara Y, Takano K, Ito S, Saruta M, Kato N, Zeniya M.; miR-425 regulates inflammatory cytokine production in CD4(+) T cells via N-Ras upregulation in primary biliary cholangitis. *J Hepatol*. 2017;66(6):1223-1230.
 10. Nakagawa H, Suzuki N, Hirata Y, Hikiba Y, Hayakawa Y, Kinoshita H, Ihara S, Uchino K, Nishikawa Y, Ijichi H, Otsuka M, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Tateishi K, Koike K.; Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. *Proc Natl Acad Sci U S A* 2017;114(19):e3806-e3815.
 11. Kumada H, Koike K., Suyama K, Ito H, Itoh H, Sugiura W.; Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs. *Hepatol Res*. 2017;47(10):1032-1041.
 12. Hirao C, Mikoshiha N, Shibuta T, Yamahana R, Kawakami A, Tateishi R, Yamaguchi H, Koike K., Yamamoto-Mitani N.; Adherence to oral chemotherapy medications among gastroenterological cancer patients visiting an outpatient clinic. *Jpn J Clin Oncol*. 2017;47(9):786-794.
 13. Gono W, Hayashi TY, Okuma H, Akahane M, Nakai Y, Mizuno S, Tateishi R, Isayama H, Koike K., Ohtomo K.; Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study. *Eur Radiol*. 2017;27(12):4941-4950.
 14. Hiramine Y, Uojima H, Nakanishi H, Hiramatsu A, Iwamoto T, Kimura M, Kawaratanani H, Terai S, Yoshiji H, Uto H, Sakaida I, Izumi N., Okita K, Koike K.; Response criteria of tolvaptan for the treatment of hepatic edema. *J Gastroenterol*. 2018;53(2):258-268.
 15. Hidaka H, Kokubu S, Sato T, Katsushima S, Izumi N., Igura T, Asahara S, Notsumata K, Osaki Y, Tsuji K, Kawanaka H, Akahoshi T, Hirota S, Matsutani S; Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double-blind, controlled trial. *Hepatol Res*. 2018;48(3):E107-E116.
 16. Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N., Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S,

- Arai Y; Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. *Lancet Gastroenterol Hepatol.* 2018;3(1):37-46.
17. Murakawa M, Asahina Y, Kawai-Kitahata F, Nakagawa M, Nitta S, Otani S, Nagata H, Kaneko S, Asano Y, Tsunoda T, Miyoshi M, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Iijima S, Tsuchiya K, Izumi N, Tohda S, Watanabe M. ; Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. *J Med Virol.* 2017;89(7):1241-1247.
 18. Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, Shimada N, Komori A, Toyoda H, Kumada T, Namisaki T, Yoshiji H, Sakamoto N, Nakagawa M, Asahina Y, Kurosaki M, Izumi N, Enomoto N, Kusakabe A, Kajiwara E, Itoh Y, Ide T, Tamori A, Matsubara M, Kawada N, Shirabe K, Tomita E, Honda M, Kaneko S, Nishina S, Suetsugu A, Hiasa Y, Watanabe H, Genda T, Sakaida I, Nishiguchi S, Takaguchi K, Tanaka E, Sugihara J, Shimada M, Kondo Y, Kawai Y, Kojima K, Nagasaki M, Tokunaga K, Tanaka Y;; Japanese Genome-Wide Association Study Group for Viral Hepatitis. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. *Gastroenterology.* *Gastroenterology* 2017;152(6):1383-1394.
 19. Tamaki N, Kurosaki M, Kusakabe A, Orito E, Joko K, Kojima Y, Kimura H, Uchida Y, Hasebe C, Asahina Y, Izumi N; ; Japanese Red Cross Hospital Liver Study Group. Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon. *J Viral Hepat.* 2017;24(8):672-678.
 20. Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M;; Liver Cancer Study Group of Japan. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. *J Gastroenterol.* 2017;52(10):1112-1121.
 21. Tamaki N, Kuno A, Matsuda A, Tsujikawa H, Yamazaki K, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Korenaga M, Mizokami M, Kurosaki M, Sakamoto M, Narimatsu H, Izumi N.; Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma. *Sci Rep.* 2017;7(1):244.
 22. Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, Tamaki N, Takada H, Higuchi M, Gotou T, Kubota Y, Takaura K, Hayashi T, Oh W, Okada M, Enomoto N, Izumi N. ; Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. *PLoS One.* 2017;12(3):e0174649.
 23. Yada N, Tamaki N, Koizumi Y, Hirooka M, Nakashima O, Hiasa Y, Izumi N, Kudo M. ; Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear

- Wave Imaging in Patients with Liver Disease. *Dig Dis.* 2017;35(6):515-520.
24. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M. ; Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. *Liver Cancer.* 2017;6(4):325-336.
 25. Kawashima T, Ikari N, Watanabe Y, Kubota Y, Yoshio S, Kanto T, Motohashi S, Shimojo N, Tsuji NM.; Double-Stranded RNA Derived from Lactic Acid Bacteria Augments Th1 Immunity via Interferon- β from Human Dendritic Cells. *Front Immunol.* 2018;9:27.
 26. Shimagaki T, Yoshizumi T, Harimoto N, Yoshio S, Naito Y, Yamamoto Y, Ochiya T, Yoshida Y, Kanto T, Maehara Y.; MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection. *Hepatology Res.* 2018;48(4):313-321.
 27. Doi H, Hayashi E, Arai J, Tojo M, Morikawa K, Eguchi J, Ito T, Kanto T, Kaplan DE, Yoshida H.; Enhanced B-cell differentiation driven by advanced cirrhosis resulting in hyperglobulinemia. *J Gastroenterol* 2018;[Epub].
 28. Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y; Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. *Lancet Gastroenterol Hepatol* 2018;3(1):37-46.
 29. Takayasu K, Arai S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N; Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤ 2 cm analysed with propensity score weighting. *Liver Int.* 2018;38(3):484-493.
 30. Kudo M; Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. *Liver Cancer* 2018;7(1):431-19.
 31. Kudo M; Combination cancer immunotherapy in hepatocellular carcinoma. *Liver Cancer* 2018;7(1):20-27.
 32. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL; Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 2018;391(10126):1163-1173.
 33. Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryou BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Chang SC, Yang L, Abada PB, Chau I; Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH Trial results by

- Child-Pugh score. *JAMA Oncol.* 2018;[Epub].
34. Kaibori M, Yoshii K, Yokota I, Hasegawa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan: Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey. *Ann Surg.* 2018;[Epub].
 35. Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T; Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. *J Gastroenterol.* 2018;[Epub].
 36. Minami Y, Minami T, Hagiwara S, Ida H, Ueshima K, Nishida N, Murakami T, Kudo M; Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma. *Eur Radiol.* 2018;28(5):1986-1993.
 37. Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. *Lancet Gastroenterol Hepatol.* 2018;3(6):424-432.
 38. Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N; Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. *Ann Surg.* 2018;[Epub].
 39. Dietrich CF, Averkiou M, Nielsen MB, Barr RG, Burns PN, Calliada F, Cantisani V, Choi B, Chammas MC, Clevert DA, Claudon M, Correas JM, Cui XW, Cosgrove D, D'Onofrio M, Dong Y, Eisenbrey J, Fontanilla T, Gilja OH, Ignee A, Jenssen C, Kono Y, Kudo M, Lassau N, Lyschchik A, Franca Meloni M, Moriyasu F, Nolsøe C, Piscaglia F, Radzina M, Saftoiu A, Sidhu PS, Sporea I, Schreiber-Dietrich D, Sirlin CB, Stanczak M, Weskott HP, Wilson SR, Willmann JK, Kim TK, Jang HJ, Vezeridis A, Westerway S; How to perform Contrast-Enhanced Ultrasound (CEUS) Ultrasound *Int Open.* 2018;4(1):E2-E15.
 40. Nishida N, Kudo M; Immune checkpoint blockade for the treatment of human hepatocellular. *Hep Res.* 2018;[Epub].
 41. Nishie A, Goshima S, Haradome H, Hatano E, Imai Y, Kudo M, Matsuda M, Motosugi U, Saitoh S, Yoshimitsu K, Crawford B, Kruger E, Ball G, Honda H; Cost-effectiveness of EOB- MRI for hepatocellular carcinoma in Japan. *Clin Ther.* 2017;39(4):738-750.
 42. Hyodo T, Yada N, Hori M, Maenishi O, Lamb P, Sasaki K, Onoda M, Kudo M, Mochizuki T, Murakami T; Multimate-

- rial decomposition algorithm for the quantification of liver fat content using fast-kilovolt-peak switching dual-energy CT: clinical evaluation. *Radiology* 2017;283(1):108-118.
43. Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H; Phase 2 Study of Lenvatinib in patients with advanced hepatocellular carcinoma. *J Gastroenterol.* 2017;52(4):512-519.
 44. Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX; Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. *J Gastroenterol.* 2017;52(4):494-503.
 45. Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone ME, Guaschino G, Sellers L, Black J, Pirisi M, Kudo M, Thimme R, Park JW, Sharma R; On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. *Aliment Pharmacol Ther.* 2017;45(8):1146-1155.
 46. Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T; Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al. *Ann Oncol.* 2017;28(4):903-904.
 47. Minami Y, Takita M, Tsurusaki M, Yagyu Y, Ueshima K, Murakami T, Kudo M; Semiquantitative prediction of early response of conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using postprocedural plain cone-beam computed tomography. *Hepatol Res.* 2017;47(3):E113-E119.
 48. Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM; Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. *J Hepatol.* 2017;66(6):1166-1172.
 49. Howell J, Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone ME, Guaschino G, Toniutto P, Black J, Sellers L, Kudo M, Pirisi M, Sharma R; Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. *Oncotarget.* 2017;8(22):36161-36170.
 50. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I; Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate040): an open-label, non-comparative, phase 1/2

- dose escalation and expansion trial. *Lancet* 2017;389(10088):2492-2502.
51. Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M; The overall survival of patients with hepatocellular carcinoma correlates with the newly defined time to progression after transarterial chemoembolization. *Liver Cancer* 2017;6(3):227-235.
 52. Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX; Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study. *Eur J Cancer*. 2017;81:17-25.
 53. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK; Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int*. 2017;11(4):317-370.
 54. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N ; Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. *Hepatology* 2017;66(2):510-517.
 55. Hagiwara S, Nishida N, Park AM, Komeda Y, Sakurai T, Watanabe T, Kudo M; Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis. *Sci Rep*. 2017;7(1):10440.
 56. Kudo M; New Era in the Treatment of Chronic Liver Diseases and Liver Cancer: State-of-the Art Progress in 2017 Digest Dis. 2017;35:493-497.
 57. Ida H, Hagiwara S, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Minami Y, Ueshima K, Nishida N, Kudo M; Hepatocellular carcinoma after achievement of sustained viral response with daclatasvir and asunaprevir in patients with chronic hepatitis C virus infection. *Digest Dis*. 2017;35(6):565-573.
 58. Iwamoto T, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Yamaguchi Y, Matsumoto Y, Nakahara M, Morimoto O, Ohashi H, Fujita N, Kudo M, Takehara T; Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a risk factor of intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma. *Digest Dis*. 2017;35(6):574-582.
 59. Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M; Impact of Tumor Factors on survival in Patients with Hepatocellular Carcinoma classified

- based on Kinki Criteria Stage B2 Digest Dis. 2017;35(6):583-588.
60. Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.; Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki criteria stages B1 and B2. Digest Dis. 2017;35(6):589-597.
 61. Ishikawa T, Imai M, Owaki T, Sato H, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T, Yoshida T, Kudo M; Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study. Digest Dis. 2017;35(6):598-601.
 62. Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, Joko K, Shimada N, Deguchi A, Ishikawa T, Imai M, Tsuji K, Michitaka K; Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis. Digest Dis. 2017;35(6):602-610.
 63. Ueshima K, Nishida N, Kudo M; Sorafenib-regorafenib sequential therapy in advanced hepatocellular carcinoma: a single-institute experience. Digest Dis. 2017;35(6):611-617.
 64. Nishida N, Kudo M; Role of immune checkpoint blockade in the treatment for human hepatocellular carcinoma. Digest Dis. 2017;35(6):618-622.
 65. Kudo M; Lenvatinib in advanced hepatocellular carcinoma. Liver Cancer 2017;6(4):253-263.
 66. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M; Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in japan: the need for a more detailed evaluation of hepatic function. Liver Cancer 2017;6(4):325-336.
 67. Hiraoka A, Michitaka K, Kumada T, Kudo M; ALBI score as a novel tool in staging and treatment planning for hepatocellular carcinoma: advantage of ALBI grade for universal assessment of hepatic function. Liver Cancer 2017;6(4):377-379.
 68. Sakurai T, Yada N, Hagiwara S, Arizumi T, Minaga K, Kamata K, Takenaka M, Minami Y, Watanabe T, Nishida N, Kudo M; Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. Cancer Sci. 2017;108(10):1996-2003.
 69. Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M ; Liver Cancer Study Group of Japan; Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol. 2017;52(10):1112-1121.
 70. Ogawa C, Morita M, Omura A, Noda T, Kubo A, Matsunaka T, Tamaki

- H, Shibatoge M, Tsutsui A, Senoh T, Nagano T, Takaguchi K, Tani J, Morishita A, Yoneyama H, Masaki T, Moriya A, Ando M, Deguchi A, Kokudo Y, Minami Y, Ueshima K, Sakurai T, Nishida N, Kudo M; Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study. *Oncology* 2017;93(S1):113-119.
71. Izumoto H, Hiraoka A, Ishimaru Y, Murakami T, Kitahata S, Ueki H, Aibiki T, Okudaira T, Miyamoto Y, Yamago H, Iwasaki R, Tomida H, Mori K, Kishida M, Tsubouchi E, Miyata H, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Michitaka K, Kudo M; Validation of newly proposed time to TACE progression (TTTP) in intermediate stage hepatocellular carcinoma cases. *Oncology* 2017;93(S1):120-126.
72. Kudo M, Arizumi T; Transarterial Chemoembolization in Combination with Molecular Targeted Agent: Lessons from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2). *Oncology* 2017;93(S1):127-134.
73. Kudo M; Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. *Oncology* 2017;93(S1):135-146.
74. Kudo M; Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. *Oncology* 2017;93(S1):147-159.
75. Nishida N, Kudo M; Oncogenic signal and tumor microenvironment in hepatocellular carcinoma. *Oncology* 2017;93(S1):160-164.
76. Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L, Abdulrahman A, Kudo M, Thimme R, Park JW, Pinato DJ; Treatment stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study. *Liver Cancer* 2017;6(4):313-324.
77. Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N ; Liver Cancer Study Group of Japan; Treatment optimization for hepatocellular carcinoma in elderly patients in a Japanese nationwide cohort *Ann Surg.* 2018;[Epub].
78. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N ; Liver Cancer Study Group of Japan; Impact of resection and ablation for single hypovascular HCC<=2 cm analyzed with propensity score weighting based on a Japanese nationwide survey *Liver Int.* 2018;38 (3):484-493.
79. Motoyama H, Tamori A, Kubo S, Uchida-Kobayashi S, Takemura S, Tanaka S, Ohfuji S, Teranishi Y, Kozuka R, Kawamura E, Hagihara A, Morikawa H, Enomoto M, Murakami Y, Kawada N; Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication *PLoS One* 2018;13 (3):e0194163.
80. Wada H, Eguchi H, Nagano H, Kubo S, Nakai T, Kaibori M, Hayashi

- M, Takemura S, Tanaka S, Nakata Y, Matsui K, Ishizaki M, Hirokawa F, Komeda K, Uchiyama K, Kon M, Doki Y, Mori M; Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis *Surg Today* 2018;48 (1):73-79.
81. Cheung TT, Han HS, She WH, Chen KH, Chow PKH, Yoong BK, Lee KF, Kubo S, Tang CN, Wakabayashi G; The Asia Pacific consensus statement on laparoscopic liver resection for hepatocellular carcinoma: A report from 7th Asia-Pacific Primary Liver Cancer Expert Meeting held Liver Cancer 2017;7 (1):28-39.
 82. Kaibori M, Kon M, Kitawaki T, Kawaura T, Hasegawa K, Kokudo N, Ariizumi S, Beppu T, Ishizu H, Kubo S, Kamiyama T, Takamura H, Kobayashi T, Kim DS, Wang HJ, Kim JM, Han DH, Park SJ, Kang KJ, Hwang S, Roh Y, You YK, Joh JW, Yamamoto M; Comparison of anatomic and non-anatomic hepatic resection for hepatocellular carcinoma *J Hepatobiliary Pancreat Sci.* 2017;24 (11):616-626.
 83. Shinkawa H, Takemura S, Tanaka S, Kubo S; Portal vein embolization: history and current indication *Visc Med.* 2017;33 (6):414-417.
 84. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M; Validation and potential of albumin-bilirubin grade and prognostication in nationwide survey of 46,681 HCC patients in Japan – need for more detailed evaluation of hepatic function *Liver Cancer* 2017;6 (4):325-336.
 85. Nakano K, Hirahara N, Motomura N, Miyata H, Takamoto S; A report based on the Japan Cardiovascular Surgery Database. 4. Valvular heart surgery. *Gen Thorac Cardiovasc Surg.* 2018;66(1):13-18.
 86. Saito A, Hirahara N, Motomura N, Miyata H, Takamoto S; Current status of cardiovascular surgery in Japan, 2013 and 2014: A report based on the Japan Cardiovascular Surgery Database 3. Coronary artery bypass surgery. *Gen Thorac Cardiovasc Surg.* 2018;66(1):43324.
 87. Hirata Y, Hirahara N, Murakami A, Motomura N, Miyata H, Takamoto S; Current status of cardiovascular surgery in Japan 2013 and 2014: A report based on the Japan Cardiovascular Surgery Database. 2: Congenital heart surgery. *Gen Thorac Cardiovasc Surg.* 2018;66(1):43197.
 88. Takamoto S, Motomura N, Miyata H, Tsukahara H; Current status of cardiovascular surgery in Japan, 2013 and 2014: A report based on the Japan Cardiovascular Surgery Database (JCVSD). 1: Mission and history of JCVSD. *Gen Thorac Cardiovasc Surg.* 2018;66(1):43103.
 89. Hirata Y, Miyata H, Hirahara N, Murakami A, Kado H, Sakamoto K, Sano S, Takamoto S; Long-Term Results of Bilateral Pulmonary Artery Banding Versus Primary Norwood Procedure. *Pediatr Cardiol.* 2018;39(1):111-119.
 90. Kodashima S, Tanaka K, Matsuda K, Fujishiro M, Saito Y, Ohtsuka K, Oda I, Katada C, Kato M, Kida M, Kobayashi K, Hoteya S, Horimatsu T, Matsuda T, Muto M, Yamamoto H, Ryozaawa

- S, Iwakiri R, Kutsumi H, Miyata H, Kato M, Haruma K, Fujimoto K, Uemura N, Kaminishi M, Tajiri H; First progress report on the Japan Endoscopy Database project. *Dig Endosc.* 2018;30(1):20-28.
91. Hiki N, Honda M, Etoh T, Yoshida K, Kodera Y, Kakeji Y, Kumamaru H, Miyata H, Yamashita Y, Inomata M, Konno H, Seto Y, Kitano S; Higher incidence of pancreatic fistula in laparoscopic gastrectomy. Real-world evidence from a nationwide prospective cohort study. *Gastric Cancer.* 2018;21(1):162-170.
 92. Nomura S, Sakamoto H, Glenn S, Tsugawa Y, Abe SK, Rahman MM, Brown JC, Ezoe S, Fitzmaurice C, Inokuchi T, Kassebaum NJ, Kawakami N, Kita Y, Kondo N, Lim SS, Maruyama S, Miyata H, Mooney MD, Naghavi M, Onoda T, Ota E, Otake Y, Roth GA, Saito E, Tabuchi T, Takasaki Y, Tanimura T, Uechi M, Vos T, Wang H, Inoue M, Murray CJL, Shibuya K; Population health and regional variations of disease burden in Japan, 1990-2015: a systematic subnational analysis for the Global Burden of Disease Study 2015. *Lancet* 2017;390(10101):1521-1538.
 93. Sawano M, Kohsaka S, Abe T, Inohara T, Maekawa Y, Ueda I, Sueyoshi K, Suzuki M, Noma S, Numasawa Y, Miyata H, Fukuda K, Smolderen KG, Spertus JA; Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multi-center Japanese PCI registry. *PLoS One* 2017;12(8):e0182687.
 94. Takeuchi H, Miyata H, Ozawa S, Udagawa H, Osugi H, Matsubara H, Konno H, Seto Y, Kitagawa Y; Comparison of Short-Term Outcomes Between Open and Minimally Invasive Esophagectomy for Esophageal Cancer Using a Nationwide Database in Japan. *Ann Surg Oncol.* 2017;24(7):1821-1827.
 95. Watanabe T, Miyata H, Konno H, Kawai K, Ishihara S, Sunami E, Hirahara N, Wakabayashi G, Gotoh M, Mori M; Prediction model for complications after low anterior resection based on data from 33,411 Japanese patients included in the National Clinical Database. *Surgery* 2017;161(6):1597-1608.
 96. Ikemura N, Sawano M, Shiraishi Y, Ueda I, Miyata H, Numasawa Y, Noma S, Suzuki M, Momiyama Y, Inohara T, Hayashida K, Yuasa S, Maekawa Y, Fukuda K, Kohsaka S; Barriers Associated With Door-to-Balloon Delay in Contemporary Japanese Practice. *Circ J.* 2017;81(6):815-822.
 97. Takai H, Miyata H, Motomura N, Sasaki K, Kunihara T, Takamoto S; Comparison of early outcomes of surgical ablation procedures for atrial fibrillation concomitant to non-mitral cardiac surgery: a Japan Adult Cardiovascular Surgery Database study. *Gen Thorac Cardiovasc Surg.* 2017;65(9):500-505.
 98. Inohara T, Kohsaka S, Yamaji K, Amano T, Fujii K, Oda H, Uemura S, Kadota K, Miyata H, Nakamura M ; J-PCI Registry Investigators1; J-PCI Registry Investigators. Impact of Institutional and Operator Volume on Short-Term Outcomes of Percutaneous Coronary Intervention: A Report From the Japanese Nationwide Registry. *JACC Cardiovasc Interv.* 2017;10(9):918-927.

99. Aoki S, Miyata H, Konno H, Gotoh M, Motoi F, Kumamaru H, Wakabayashi G, Kakeji Y, Mori M, Seto Y, Unno M; Risk factors of serious postoperative complications after pancreaticoduodenectomy and risk calculators for predicting postoperative complications: a nationwide study of 17,564 patients in Japan. *J Hepatobiliary Pancreat Sci.* 2017;24(5):243-251.
100. Numasawa Y, Sawano M, Miyata H, Ueda I, Noma S, Suzuki M, Kuno T, Kodaira M, Maekawa Y, Fukuda K, Kohsaka S; Outcomes After Percutaneous Coronary Intervention of Acute Coronary Syndrome Complicated With Cardiopulmonary Arrest (from a Japanese Multicenter Registry). *Am J Cardiol.* 2017;119(8):1173-1178.
101. Miyahara S, Miyata H, Motomura N, Takamoto S, Okita Y; Japan Cardiovascular Surgery Database Organization; Japan Cardiovascular Surgery Database Organization. Clinical significance of chronic obstructive pulmonary disease in patients undergoing elective total arch replacement: analysis based on the Japan Adult Cardiovascular Surgery Database. *Eur J Cardiothorac Surg.* 2017;51(4):761-766.
102. Inohara T, Kohsaka S, Miyata H, Sawano M, Ueda I, Maekawa Y, Fukuda K, Jones PG, Cohen DJ, Zhao Z, Spertus JA, Smolderen KG; Prognostic Impact of Subsequent Acute Coronary Syndrome and Unplanned Revascularization on Long-Term Mortality After an Index Percutaneous Coronary Intervention: A Report From a Japanese Multicenter Registry. *J Am Heart Assoc.* 2017;6(11):e006529.
103. Kikuchi H, Miyata H, Konno H, Kamiya K, Tomotaki A, Gotoh M, Wakabayashi G, Mori M; Development and external validation of preoperative risk models for operative morbidities after total gastrectomy using a Japanese web-based nationwide registry. *Gastric Cancer* 2017;20(6):987-997.
104. Endo S, Ikeda N, Kondo T, Nakajima J, Kondo H, Yokoi K, Chida M, Sato M, Toyooka S, Yoshida K, Okada Y, Sato Y, Okada M, Okumura M, Chihara K, Fukuchi E, Miyata H; Model of lung cancer surgery risk derived from a Japanese nationwide web-based database of 78 594 patients during 2014-2015. *Eur J Cardiothorac Surg.* 2017;52(6):1182-1189.
105. Shimizu H, Hirahara N, Motomura N, Miyata H, Takamoto S; Current status of cardiovascular surgery in Japan, 2013 and 2014: A report based on the Japan Cardiovascular Surgery Database. 4. Valvular heart surgery. *Gen Thorac Cardiovasc Surg.* 2017;65(12):671-678.
106. Kawamoto S, Miyata H, Motomura N, Tanemoto K, Takamoto S, Saiki Y; Surgical Outcomes of Isolated Coronary Artery Bypass Grafting for Acute Coronary Syndrome - Based on the Japan Adult Cardiovascular Surgery Database. *Circ J.* 2017;82(1):123-130.
107. Tamura Y, Kumamaru H, Satoh T, Miyata H, Ogawa A, Tanabe N, Hatano M, Yao A, Abe K, Tsujino I, Fukuda K, Kimura H, Kuwana M, Matsubara H, Tatsumi K; Japan PH Registry (JAPHR) Network.; Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in

- Japanese Patients With Pulmonary Arterial Hypertension. *Circ J.* 2017;82(1):275-282.
108. Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, Liver Cancer Study Group of J.; Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. *Ann Surg* 2018;[Epub].
109. Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, Tanaka Y, Tateishi R, Hikiba Y, Misumi K, Tanaka M, Hayashi A, Shibahara J, Fukayama M, Arita J, Hasegawa K, Hirschfield H, Hoshida Y, Hirata Y, Otsuka M, Tateishi K, Koike K.; CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. *Gut* 2018;[Epub].
110. Sato M, Tateishi R, Yasunaga H, Matsui H, Horiguchi H, Fushimi K, Koike K.; Mortality and hemorrhagic complications associated with radiofrequency ablation for treatment of hepatocellular carcinoma in patients on hemodialysis for end-stage renal disease: A nationwide survey. *J Gastroenterol Hepatol.* 2017;32(11):1873-1878.
111. Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX.; Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. *J Gastroenterol.* 2017;52(4):494-503.
112. Hirao C, Mikoshiba N, Shibuta T, Yamahana R, Kawakami A, Tateishi R, Yamaguchi H, Koike K, Yamamoto-Mitani N.; Adherence to oral chemotherapy medications among gastroenterological cancer patients visiting an outpatient clinic. *Jpn J Clin Oncol.* 2017;47(9):786-794.
113. Gono W, Hayashi TY, Okuma H, Akahane M, Nakai Y, Mizuno S, Tateishi R, Isayama H, Koike K, Ohtomo K.; Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study. *Eur Radiol.* 2017;27(12):4941-4950.
- 2) 学会発表
1. Izumi N.; Understanding why some HCV patients fail to achieve SVR. *Hepatology in Asia*, Dec.2,2017, Hong Kong
 2. Izumi N, Takehara T, Chayama K, Yatsushashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, K.C Huang, Shampa De-Oertel, Brian L. McNabb, Gregory Camus, John McNally, Diana M. Brainard, John G. McHutchison, Mochida S, Mizokami M; Efficacy and Safety of Sofosbuvir-Velpatasvir Plus Ribavirin for 12 or 24 Weeks in Genotype 1 or 2 HCV-Infected Japanese Patients with Prior Treatment Failure to DAA-Based Regimens. *AASLD*, Oct.21,2017, U.S.A.
 3. 辻恵二、黒崎雅之、泉並木：全国多施設共同研究による難治性 C 型肝炎に対する Ledipasvir/Sofosbuvir の治療効果 ワークショップ 1 第 53 回日本肝臓学会総会 (平成 29 年 6 月 8-9 日、広島市)
 4. 黒崎雅之、板倉潤、泉並木：DCV/ASV 治

- 療不成功例の薬剤耐性変異および再治療成績：全国多施設共同研究 ワークショップ 1 第 53 回日本肝臓学会総会（平成 29 年 6 月 8-9 日、広島市）
5. 樋口麻友、黒崎雅之、泉並木：MR elastography による肝線維化評価および食道静脈瘤の予後 ワークショップ 6 第 53 回日本肝臓学会総会（平成 29 年 6 月 8-9 日、広島市）
 6. 高田ひとみ、黒崎雅之、泉並木：血清 WFA-sialylated MUC1 による肝癌悪性度評価および再発の検討 ワークショップ 9 第 53 回日本肝臓学会総会（平成 29 年 6 月 8-9 日、広島市）
 7. 久保田洋平、黒崎雅之、泉並木：肝硬変に伴う脳機能低下に対する L-カルニチンの効果 ワークショップ 11 第 53 回日本肝臓学会総会（平成 29 年 6 月 8-9 日、広島市）
 8. 黒崎雅之、板倉潤、泉並木：DCV/ASV 治療不成功例の薬剤耐性変異、再治療の状況、および SOF/LDV による再治療の成績：全国多施設共同研究 シンポジウム 7 第 103 回日本消化器病学会総会（平成 29 年 4 月 20 日、東京都新宿区）
 9. 中西裕之、黒崎雅之、泉並木：進行肝癌ソラフェニブ治療例の予後予測の検討 パネルディスカッション 10 第 103 回日本消化器病学会総会（平成 29 年 4 月 20 日、東京）
 10. 板倉潤、黒崎雅之、泉並木：B 型肝炎治療薬の治療効果比較—エンテカビル先行テノホビル導入症例における検討— パネルディスカッション 8 第 103 回日本消化器病学会総会（平成 29 年 4 月 20 日、東京）
 11. Kudo M: Locally advanced, non-resectable disease. ESMO ASIA 2017, Nov.17-19, 2017, Singapore
 12. 工藤正俊：急激に変貌する肝癌の薬物療法：免疫療法を含めて. 講演 II. 中・四国肝疾患研究会（平成 29 年 12 月 28 日、高松市）
 13. 工藤正俊：基調講演「進行肝細胞癌治療における最新治療：基礎と臨床の立場から」シンポジウム 7 第 42 回日本肝臓学会西部会（平成 29 年 11 月 30 日、福岡市）
 14. 河野匡志, 西田直生志, 千品寛和, 南 知宏, 有住忠晃, 田北雅弘, 矢田典久, 萩原智, 南 康範, 上嶋一臣, 工藤正俊：DAA 投与における SVR 後の AFP 異常値と関連する臨床背景の検討. 一般演題. 第 42 回日本肝臓学会西部会（平成 29 年 11 月 30 日、福岡市）
 15. 福永朋洋, 萩原 智, 半田康平, 高田隆太郎, 岡本彩那, 南 知宏, 河野匡志, 千品寛和, 有住忠晃, 田北雅弘, 南 康範, 依田 広, 上嶋一臣, 西田直生志, 工藤正俊：胃への遠隔転移を認めた肝細胞癌の一例. 若手医師症例報告奨励賞 第 42 回日本肝臓学会西部会（平成 29 年 11 月 30 日、福岡市）
 16. 工藤正俊：特別講演「肝細胞癌薬物治療のブレイクスルー」 第 168 回群馬肝癌検討会特別講演会（平成 29 年 11 月 15 日、前橋市）
 17. 新川寛二, 田中肖吾, 竹村茂一, 伊藤得路, 青田尚哲, 宮崎 徹, 江田将樹, 久保正二：C 型肝炎関連肝細胞癌と比較した非 B 非 C 型肝炎細胞癌切除症例の臨床病理学的特徴と治療成績の検討 第 46 回近畿肝臓外科研究会（2018 年 2 月 17 日、大阪市）
 18. 田中肖吾, 竹村茂一, 新川寛二, 伊藤得路, 宮崎 徹, 江田将樹, 青田尚哲, 久保正二：高度肝機能障害を有する肝細胞癌に対する腹腔鏡下肝切除術の有用性 第 11 回肝臓内視鏡外科研究会（2017 年 12 月 6 日、京都市）
 19. 田中肖吾, 竹村茂一, 久保正二：手技の定型化は腹腔鏡下肝切除の治療成績を向上させたか 第 42 回日本肝臓学会西部会

(2017年11月30日、福岡市)

20. 田中肖吾, 竹村茂一, 新川寛二, 伊藤得路, 宮崎 徹, 江田将樹, 青田尚哲, 久保正二: 腹腔鏡下肝切除術は SSI の頻度を減少させたかー開腹下肝切除との比較検討ー 第30回日本外科感染症学会総会学術集会 (2017年11月29日、東京)
21. 田中肖吾, 海堀昌樹, 上野昌樹, 和田浩志, 廣川文鋭, 中居卓也, 飯田洋也, 江口英利, 林 道廣, 久保正二: 破裂肝細胞癌の外科治療成績に関する多施設共同研究: 傾向スコアマッチングによる比較検討試験 第79回日本臨床外科学会総会 (2017年11月23日、東京)
22. 上野昌樹, 中居卓也, 林 道廣, 廣川文鋭, 江口英利, 和田浩志, 海堀昌樹, 松井康輔, 竹村茂一, 田中肖吾, 松本正孝, 井上善博, 石崎守彦, 山上裕機, 久保正二: 肝細胞癌の RFA 治療後局所再発症例に対するセルベージ肝切除の意義: 多施設共同後ろ向き観察研究
23. 第79回日本臨床外科学会総会 (2017年11月23日、東京)

H. 知的財産権の出願・登録状況 (予定を含む。)

1. 特許取得
なし
2. 実用新案登録
なし
3. その他
なし